Playback speed
10 seconds
ASCO® 2023 Insights: "ARC-7: Randomized Phase 2 Study of Domvanalimab + Zimberelimab ± Etrumadenant vs. Zimberelimab in 1L PD-L1-High mNSCLC"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Melissa Johnson
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Melissa Johnson
816 views
June 9, 2023
Login to view comments.
Click here to Login